Rich Whitely, MD

Virologist

• Gilead's Board of Director

• Distinguished Professor Loeb Scholar Chair in Pediatrics, and Professor of Microbiology, Medicine and Neurosurgery, UAB

• Co-Founder & Co-Director, 

• Alabama Drug Discovery Alliance

• 380 Publications

• Obama H1N1 Task Force

• Remdesivir was Originally Developed by Dr Whitley’s team at UAB

Abel DeLaRosa, PhD

Virologist

• CEO, Director, co-founder of Antios Therapeutics

• Chief Scientific Officer of Drug Innovation Ventures at Emory

• Led acquisition of Pharmasset by Gilead Sciences (NASDAQ: GILD) for $11.5 billion in 2012

• Led Drug Development Programs for the Treatment of HIV, Hepatitis B and C, including Sofosbuvir 

John Thomas, CPA

CFO/Director/Audit Chair

• CorMatrix Cardiovascular DemeRx, Inc.

• MiMedx Group, Inc. 

• DARA BioSciences

• GMP Companies 

• MRI Interventions

• EnterMed, Inc. 

• Medicis Pharm Corp. 

• CytRx Corp

Rick Keefer

Director

• 30-year Pharma industry veteran with broad-based experience in leading commercial operations.

• Seven-time winner of Pharma Voice’s top 100 leaders in healthcare

• Executive roles at Pharmacia, Pfizer, Wyeth, Biovail and Publicis Health

Skip Pridgen, MD Founder

Director

• Company Founder

• Board- certified surgeon practicing with Tuscaloosa Surgical Associates, P.C.

• Spent nearly 20 years searching for effective treatments in IBS, FM, and CFS/ME

• Served as a physician and surgeon in the United States Navy

Greg Duncan

Director

• FPO

Rick Burch

Director

• FPO